Ποια είναι η τιμή για DelMar Pharmaceuticals, Inc. (DMPWW)

Η τιμή για DelMar Pharmaceuticals, Inc. (DMPWW) είναι $0.005

Ποια είναι η κεφαλαιοποίηση αγοράς για DelMar Pharmaceuticals, Inc. (DMPWW)

Η κεφαλαιοποίηση αγοράς για DelMar Pharmaceuticals, Inc. (DMPWW) είναι $1.74K

DelMar Pharmaceuticals, Inc. (DMPWW) Τιμή και Κεφαλαιοποίηση Αγοράς

Kintara Therapeutics, Inc., previously known as DelMar Pharmaceuticals, Inc. until its rebranding in August 2020, operates as a clinical-stage pharmaceutical firm. Headquartered in San Diego, California, and established in 2009, the company is committed to advancing and bringing to market anti-cancer treatments for patients. Its development pipeline includes two advanced therapeutic candidates. One is VAL-083, a DNA-targeting agent poised for Phase III trials, designed to combat various drug-resistant solid tumors such as glioblastoma multiforme, ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma. The other is REM-001, a late-stage photodynamic therapy intended for conditions like cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and addressing access graft failure in hemodialysis patients. Kintara Therapeutics also maintains a strategic alliance with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. for the manufacturing and commercialization of VAL-083 within the Chinese market.

Η τιμή για DMPWW	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$15,477,429 $1.74K	NVDA	$5.383T	+309,548,585,950.26%
$12,746,608 $1.74K	AAPL	$4.434T	+254,932,164,937.09%
$11,952,412 $1.74K	GOOG	$4.157T	+239,048,248,617.73%
$10,532,232 $1.74K	MSFT	$3.663T	+210,644,634,308.60%
$8,312,428 $1.74K	AMZN	$2.891T	+166,248,564,985.39%

Η τιμή για DMPWW

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$15,477,429 $1.74K